BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12368068)

  • 1. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections.
    De Clercq E
    Trends Pharmacol Sci; 2002 Oct; 23(10):456-8. PubMed ID: 12368068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cidofovir in the treatment of poxvirus infections.
    De Clercq E
    Antiviral Res; 2002 Jul; 55(1):1-13. PubMed ID: 12076747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives.
    Neyts J; De Clercq E
    Antiviral Res; 2003 Jan; 57(1-2):25-33. PubMed ID: 12615300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
    Smee DF; Sidwell RW
    Antiviral Res; 2003 Jan; 57(1-2):41-52. PubMed ID: 12615302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
    De Clercq E; Neyts J
    Rev Med Virol; 2004; 14(5):289-300. PubMed ID: 15334537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
    De Clercq E
    Expert Rev Anti Infect Ther; 2003 Jun; 1(1):21-43. PubMed ID: 15482100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.
    De Clercq E
    Clin Microbiol Rev; 2001 Apr; 14(2):382-97. PubMed ID: 11292644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
    De Clercq E
    Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
    Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
    Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir.
    Smee DF; Bailey KW; Wong M; Sidwell RW
    Antiviral Res; 2000 Sep; 47(3):171-7. PubMed ID: 10974369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cidofovir Activity against Poxvirus Infections.
    Andrei G; Snoeck R
    Viruses; 2010 Dec; 2(12):2803-30. PubMed ID: 21994641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
    Smee DF; Bailey KW; Sidwell RW
    Chemotherapy; 2003 Jun; 49(3):126-31. PubMed ID: 12815205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
    Keith KA; Hitchcock MJ; Lee WA; HolĂ˝ A; Kern ER
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.
    Bray M; Martinez M; Smee DF; Kefauver D; Thompson E; Huggins JW
    J Infect Dis; 2000 Jan; 181(1):10-9. PubMed ID: 10608745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of orf poxvirus lesion with cidofovir cream.
    McCabe D; Weston B; Storch G
    Pediatr Infect Dis J; 2003 Nov; 22(11):1027-8. PubMed ID: 14614378
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiviral prophylaxis of smallpox.
    Bray M; Roy CJ
    J Antimicrob Chemother; 2004 Jul; 54(1):1-5. PubMed ID: 15163655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge.
    Roy CJ; Baker R; Washburn K; Bray M
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2933-7. PubMed ID: 12936997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.
    Zabawski EJ; Cockerell CJ
    J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):741-5. PubMed ID: 9810890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of potential anti-poxvirus agents.
    Kern ER
    Antiviral Res; 2003 Jan; 57(1-2):35-40. PubMed ID: 12615301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of topical and intralesional cidofovir.
    Zabawski EJ
    Dermatol Online J; 2000 Sep; 6(1):3. PubMed ID: 11328613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.